Bone News and Research

RSS

NovaBone Products relocates operations division to expanded and upgraded facilities

NovaBone Products, LLC has announced the relocation of its operations division to expanded and upgraded facilities where it will meet increasing demands of higher sales to a more geographically diverse distributor network.

4 Feb 2010

New ‘smart coating’ enables safe surgical implants; prevents infections post surgery

Researchers at North Carolina State University have developed a "smart coating" that helps surgical implants bond more closely with bone and ward off infection.

4 Feb 2010

Study sheds new light on cancer metastasis

Some cells are natural rule-breakers. Neural crest cells for example, not only migrate throughout the body during development (most cells are more selective in their wandering), they are also more developmentally flexible than their predecessors (a no-no for nearly all cell types).

4 Feb 2010

Blood cytokine levels may help in predicting arthritic rheumatism

Levels of inflammatory proteins, so-called cytokines, are elevated in the blood even before the onset of arthritic rheumatism. This means that such blood samples could be used to predict the development of the disease and thereby make it possible to prevent the pathological process, according to an article by Umeå researcher Solbritt Rantapää-Dahlqvist and her associates in the journal Arthritis and Rheumatism.

4 Feb 2010

Researchers uncover new mechanism to protect individuals from serious complications of obesity

Although obesity is a risk factor for diabetes and coronary heart disease worldwide, only some obese individuals go on to develop these metabolic complications, while others are relatively protected. Defining these protective factors could help scientists prevent disease in the wider population.

4 Feb 2010

Shire's clinical study results for treatment of Gaucher disease to be presented at LDN World Symposium

Shire plc, the global specialty biopharmaceutical company, today announced that data from one of three Phase III clinical trials for velaglucerase alfa, the company's enzyme replacement therapy (ERT) in development for the treatment of Type 1 Gaucher disease, will be presented at the Lysosomal Disease Network (LDN) World Symposium, February 10-12, 2010 in Miami, Florida.

4 Feb 2010

New study compares two treatment options for clubfoot - Ponseti method and surgical treatment

Clubfoot affects one in a thousand babies born in the United States, but with proper corrective treatment and follow-up, infants born with clubfoot can have feet compatible with an active, normal lifestyle.

3 Feb 2010

Patient-specific knee resurfacing implants now available for Inland Empire residents

Inland Empire residents suffering from knee pain can finally take a sigh of relief thanks to the availability of minimally traumatic, patient-specific knee resurfacing implants.

3 Feb 2010

SNM Clinical Trials Network Workshop: Experts to discuss usage of molecular imaging

On Feb. 2, the final day of the second annual SNM Clinical Trials Network Workshop, experts working in various facets of the molecular imaging community met in Albuquerque, N.M., to discuss the nuts and bolts of using imaging in clinical trials and the challenges and opportunities ahead in the regulatory landscape.

3 Feb 2010

New 3D scaffold for stem cell renewal

Medical researchers were shocked to discover that virtually all human embryonic stem cell lines being used in 2005 were contaminated. Animal byproducts used to line Petri dishes had left traces on the human cells. If those cells had been implanted in a human body they likely would have been rejected by the patient's immune system.

3 Feb 2010

Nanotope’s bioactive nanofiber system promotes cartilage regeneration

Arrowhead Research Corporation today announced publication in Proceedings of the National Academy of Sciences (PNAS) of a study using Nanotope’s lead compound for cartilage regeneration. The study’s authors, which include Nanotope co-founder Dr. Samuel Stupp, showed that Nanotope’s bioactive nanofiber system promotes the growth of new cartilage in a rabbit model. The treatment is engineered to repair cartilage defects by working with an animal’s own bone marrow stem cells to stimulate the production of new natural cartilage.

3 Feb 2010

Nanotope publishes preclinical data demonstrating cartilage regeneration

Arrowhead Research Corporation has announced publication in Proceedings of the National Academy of Sciences (PNAS) of a study using Nanotope's lead compound for cartilage regeneration.

3 Feb 2010

Banner Health to use Premier's Web-based labor benchmarking solution

Banner Health is expanding its relationship with the Premier healthcare alliance to include Premier’s OperationsAdvisor® (OA) Web-based labor benchmarking solution.

3 Feb 2010

VIDAZA prolongs survival in AML patients

The Myelodysplastic Syndromes (MDS) Foundation says a study published this week in the Journal of Clinical Oncology concludes VIDAZA (azacitidine) “prolongs survival and is well tolerated” in patients with acute myeloid leukemia (AML) - an aggressive form of leukemia that in many cases progresses from MDS.

3 Feb 2010

FDA accepts Teva Pharmaceutical Industries' BLA for XM02 G-CSF

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing Teva’s Biologics License Application (BLA) for XM02, a granulocyte colony-stimulating factor (G-CSF) for the reduction in the duration of severe neutropenia and the incidence of febrile neutropenia in patients treated with established myelosuppressive chemotherapy for cancer.

2 Feb 2010

Cytheris broadens patent protection for recombinant human interleukin-7

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application "Glycosylated IL-7, Preparation and Uses", US Patent Application Number 11/996,176. The Notice of Allowance is the USPTO’s official communication that the Company’s application has successfully completed examination and that a patent will be issued.

2 Feb 2010

FDA requests additional data on CMC section of NDA for taliglucerase alfa from Protalix BioTherapeutics

Protalix BioTherapeutics, Inc. announced today that, in connection with the New Drug Application (NDA) filed by the Company in December 2009 for taliglucerase alfa for the treatment of Gaucher disease, the U.S. Food and Drug Administration (FDA) has requested additional data regarding the Chemistry, Manufacturing and Controls (CMC) section of the NDA.

2 Feb 2010

Safer bone marrow transplants

If a team of American scientists are right, bone marrow transplants may become safer and more available to people in need of donations. In a new research paper appearing in the February 2010 print edition of the Journal of Leukocyte Biology (http://www.jleukbio.org), they explain how an anti-inflammatory agent called "ATL146e" may significantly improve the likelihood of success for bone marrow transplants by preventing or halting the progression of graft-versus-host disease, a complication of bone marrow transplants in which the donor marrow attacks the host. Although very rare, graft-versus-host disease can also occur after blood transfusions.

2 Feb 2010

Minimally invasive living donor liver retrieval for pediatric transplant

NewYork-Presbyterian Morgan Stanley Children's Hospital is the only medical center in the United States to offer minimally invasive liver donation for pediatric transplantation. Surgeons use a laparoscopic technique to remove a section of liver from a living donor for implantation in a pediatric patient -- typically a parent donating to their child. The innovative approach promises dramatically improved recovery for the donor.

2 Feb 2010

Elbit Imaging intends to restructure its bio-tech and medical holdings under a subsidiary

Elbit Imaging ("Elbit Imaging" "Company") announced today that it intends to restructure its bio-tech and medical holdings (InSightec - 60%, and Gamida Cell - 28%; both on a fully diluted basis) under a wholly-owned Elbit Imaging subsidiary and to offer shares of such subsidiary in a public offering on the Tel Aviv Stock Exchange ("IPO").

2 Feb 2010

Bone News and Research

NovaBone Products relocates operations division to expanded and upgraded facilities

New ‘smart coating’ enables safe surgical implants; prevents infections post surgery

Study sheds new light on cancer metastasis

Blood cytokine levels may help in predicting arthritic rheumatism

Researchers uncover new mechanism to protect individuals from serious complications of obesity

Shire's clinical study results for treatment of Gaucher disease to be presented at LDN World Symposium

New study compares two treatment options for clubfoot - Ponseti method and surgical treatment

Patient-specific knee resurfacing implants now available for Inland Empire residents

SNM Clinical Trials Network Workshop: Experts to discuss usage of molecular imaging

New 3D scaffold for stem cell renewal

Nanotope’s bioactive nanofiber system promotes cartilage regeneration

Nanotope publishes preclinical data demonstrating cartilage regeneration

Banner Health to use Premier's Web-based labor benchmarking solution

VIDAZA prolongs survival in AML patients

FDA accepts Teva Pharmaceutical Industries' BLA for XM02 G-CSF

Cytheris broadens patent protection for recombinant human interleukin-7

FDA requests additional data on CMC section of NDA for taliglucerase alfa from Protalix BioTherapeutics

Safer bone marrow transplants

Minimally invasive living donor liver retrieval for pediatric transplant

Elbit Imaging intends to restructure its bio-tech and medical holdings under a subsidiary

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News